The BA.4 and BA.5 sub-variants of Omicron are estimated to make up about 8.3 percent and 13.3 percent of the coronavirus variants in the United States as of June 11, the U.S. Centers for Disease Control and Prevention (CDC) said on Tuesday.
Posts
U.S. Food and Drug Administration staff reviewers on Sunday said Pfizer-BioNTech’s COVID-19 vaccines were effective and safe for use in children aged 6 months to 4 years.
Diabetes may increase the risk of long COVID, new analyses of seven previous studies suggest. Researchers have also found that babies born to mothers who had COVID-19 while pregnant may be at higher than average risk for problems with brain development involved in learning, focusing, remembering, and developing social skills.
Moderna announced that the company’s Omicron-containing COVID-19 booster candidate, mRNA-1273.214, demonstrated superior antibody response against Omicron in its Phase II/III study. The booster contains the original COVID-19 vaccine, Spikevax, as well as a vaccine targeting the Omicron variant.
The BA.4 and BA.5 sub-variants of Omicron are estimated to make up nearly 5% and 8% of the coronavirus variants in the United States as of June 4, the U.S. Centers for Disease Control and Prevention (CDC) said on Tuesday.
Pfizer Inc.’s (PFE.N) antiviral treatment Paxlovid reduces COVID-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, according to a new study in Israel conducted during the rise of the Omicron variant of the coronavirus.
Omicron breakthrough infections may spare young hearts; no need to delay mammogram after vaccination
Antibodies, BioNTech, BNT162b2 (Pfizer and BioNTech), Breakthrough COVID-19, Cardiovascular, COVID-19 booster shots, COVID-19 shots, COVID-19 Studies, COVID-19 Vaccinations, COVID-19 Vaccines, Covid-19 Variants, Heart, Immune Cells, Immune Response, Lancet Infectious Diseases, Mammography, Messenger RNA (mRNA) Vaccines, Omicron (B.1.1.529) (South Africa), Pfizer, R&D, T-Cells, WomenThe Omicron variant of the coronavirus does not have a negative effect on cardiovascular health in young adults who have been vaccinated, a small study suggests. Additionally, women should not delay routine mammograms after receiving a COVID-19 mRNA vaccine, experts now say.